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Background: Primary biliary cirrhosis (PBC), characterized by cholangitis and loss of intrahepatic 
small bile ducts, predominantly affects middle-aged females. We have reported that fractalkine 
expression associated with chronic inflammation is observed in the damaged bile ducts and 
periductal vessels of PBC patients, which is closely associated with chronic cholangitis. Aims: We 
investigated the association between serum fractalkine levels and clinicopathological findings in 
PBC patients. Methods: Liver biopsy specimens before ursodeoxycholic acid (UDCA) treatment and 
serum samples at the time of liver biopsy and 1 and 2 years after treatment were obtained from 68 
PBC patients (M/F = 14/54). Serum fractalkine levels were measured by enzyme-linked 
immunosorbent assay (ELISA), and their association with clinicopathological findings (liver 
function data, autoantibodies, cholangitis activity, hepatitis activity, fibrosis, bile duct loss, and 
orcein-positive granules) was analyzed. Results: Serum fractalkine levels were in the range of 
0.1–33.2 ng/ml (average, 3.2 ng/ml). They were increased in PBC patients with high degrees of 
cholangitis activity, a mild degree of hepatitis activity, fibrosis, orcein-positive granules, and early 
stages. In cases with high serum fractalkine levels, those who exhibited good biochemical responses 
to treatment mostly showed improved serum fractalkine levels after treatment. Conclusion: Serum 
fractalkine levels of PBC patients were high in cases with marked cholangitis activity at early stages. 
In addition, they closely correlated with the effect of therapy, indicating that fractalkine plays a role 
in the pathogenesis of initial cholangitis in early stage PBC and consequent chronic cholangitis. 
Thus, our results suggest that fractalkine is a good candidate for molecular-targeted treatment. 
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 Fractalkine (CX3CL1) plays an important role in leukocytes migration to target sites under both 
physiological and pathological conditions. Unlike other chemokines, fractalkine is a 
membrane-bound protein that can be shed in soluble chemotactic form following cleavage by a 
disintegrin and metalloprotease (ADAM) 10 and ADAM17 [1]. Soluble fractalkine is known to be a 
potent chemoattractant for CD8-positive and CD4-positive T cells, CD16-positive natural killer cells, 
and macrophage/monocytes expressing its receptor (CX3CR1), and promotes strong adhesion of 
these leukocytes in an integrin-independent manner. Therefore, fractalkine signaling is thought to be 
involved in the development of chronic inflammation, as has been reported in cases of rheumatoid 
arthritis (RA), atherosclerosis, inflammatory bowel disease (IBD), and rejection of implanted organs, 
and genetic polymorphisms of fractalkine have been speculated to increase disease susceptibility [2]. 
Moreover, fractalkine was recently noted as a molecular target of therapeutic agents for RA and IBD, 
and anti-inflammatory treatments using anti-CX3CR1 antibody have been developed for RA and an 
animal model of heart transplantation [2,3]. 
 Primary biliary cirrhosis (PBC) mainly affects middle-aged females; histologically, the 
interlobular bile ducts are primarily damaged with characteristic findings such as chronic 
nonsuppurative destructive cholangitis (CNSDC) followed by progressive loss of bile ducts [4]. 
There is considerable evidence that bile duct damage is mediated by autoreactive or cytotoxic T cells 
[5-8], and the molecular mechanisms responsible for the migration of pathogenic T cells around or 
within bile ducts have been clarified over the past several years. We previously reported that the 
level of fractalkine is significantly elevated in the sera of PBC patients and in small bile ducts, 
particularly those that are damaged. In addition, vascular endothelial cells expressing fractalkine is 
increased in PBC [9], suggesting that fractalkine is an important mediator associated with the 
continuous portal, particularly periductal, inflammation of PBC. Moreover, the expression of 
fractalkine in bile ducts is reported to be associated with innate immunity via Toll-like receptor 
(TLR) 3 and TLR4 in vascular endothelial cells, infiltrating mononuclear cells, and biliary epithelial 
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cells [10,11]. 
 Fractalkine is an important chemokine closely associated with the pathogenesis of 
cholangiopathy, and is likely involved in the continuous inflammation of chronic cholangitis in PBC. 
In this study, we investigated serum fractalkine levels in PBC patients and their association with 
clinicopathological findings. 
 
MATERIALS and METHODS 
  
 Subjects and clinical information: Sixty-eight patients with PBC were selected from registered 
files of the National Hospital Organization (NHO) Nagasaki Medical Center. The patients included 
14 males and 54 females with average ages of 53 and 59 years, respectively. Serum samples were 
obtained at the diagnosis of PBC or before ursodeoxycholic acid (UDCA) treatment for PBC and 1 
and 2 years after starting UDCA treatment, and liver function data [aspartate transaminase (AST), 
alkaline phosphatase (ALP) levels], IgM levels, and levels of autoantibodies [anti-mitochondrial 
antibody (AMA), anti-centromere antibody, and anti-gp210 antibody] at were analyzed at each time 
point. The reserved serum samples were used for the measurement of soluble fractalkine with an 
enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN). Liver biopsy 
specimens from all cases were also obtained at the time PBC was diagnosed, before treatment. 
 Diagnosis of PBC and criteria of UDCA effect: The diagnosis of PBC and biochemical 
response to UDCA were defined following criteria established by the Intractable Hepato-Biliary 
Disease Study Group in Japan. Patients whose condition meets one of the below criteria were 
diagnosed with PBC. (1) Histologically observed chronic nonsuppurative destructive cholangitis 
(CNSDC) and laboratory findings not contradicting PBC; (2) positive AMA and/or anti-pyruvate 
dehydrogenase (PDH) antibody, CNSDC not histologically observed but histological findings 
compatible with PBC; or (3) histological examination not performed, but positive AMA or anti-PDH 
antibodies and clinical findings and course indicating PBC. Biochemical response to UDCA was as 
follows: good, normalization of serum ALP, ALT, and IgM within 2 years of starting UDCA 
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treatment; fair, serum ALP, ALT, and IgM within <1.5 upper limit of normal (ULN) 2 years after 
starting UDCA treatment; and poor, serum ALP, ALT, and IgM within ≥1.5 ULN 2 years after 
starting UDCA treatment.  
 Histological examination: More than 10 4-μm-thick sections were prepared from each 
paraffin-embedded block; several were stained with hematoxylin–eosin (HE), Gomori’s reticulum, 
and Orcein stain for histological diagnosis, grading, and staging.  
 The grading system and new staging system proposed by Nakanuma [12] were used to evaluate 
disease activity and stage. In summary, chronic cholangitis activity (CA) was categorized into four 
grades (CA0–3) according to the degree and distribution. CA0 (no activity) was defined as absent or 
ambiguous bile duct damage. In CA1 (mild activity), one bile duct showed evident chronic 
cholangitis. In CA2 (moderate activity), two or more bile ducts were affected. In CA3 (marked 
activity), at least one damaged bile duct showed CNSDC and/or granulomatous cholangitis. Evident 
chronic cholangitis was defined as a damaged bile duct entirely surrounded by mild to moderate, 
duct-oriented lymphoplasmacytic inflammation. Hepatitis activity (HA) was also categorized into 
four grades (HA0–3) according to the presence and degree of interface hepatitis and lobular hepatitis. 
In HA0 (no activity), interface hepatitis was not present. The presence of interface hepatitis affecting 
at least 10 continuous hepatocytes at the interface of one portal tract or fibrous septum was 
categorized as HA1 (mild activity) and in two or more portal tracts or fibrous septa as HA2 
(moderate activity). In HA3 (marked activity), interface hepatitis affecting at least 20 continuous 
hepatocytes at the limiting plate in more than half of the portal tracts or fibrous septa was present 
throughout the specimen, with entrapment of hepatocytes in the expanded portal tracts. Although no 
or minimum lobular hepatitis was found in HA0, mild to moderate lobular hepatitis was observed in 
HA1 and HA2, and moderate lobular hepatitis in HA3. Occasional zonal necrosis and bridging 
necrosis was regarded as HA3.  
 Three factors were evaluated for the new staging system: fibrosis, bile duct loss, and 
Orcein-positive granule deposition. These three items were scored as follows. For fibrosis, a score of 
0 indicated almost no fibrosis or fibrosis limited to the portal tracts, a score of 1 indicated fibrosis 
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extending beyond the portal area with occasional incomplete septal fibrosis, a score of 2 indicated 
completely connecting septal fibrosis or bridging fibrosis with variable lobular distortion, and a 
score of 3 was assigned for cirrhosis (extensive fibrosis with regenerative nodules). For bile duct loss, 
interlobular bile ducts were evaluated in well-formed portal tracts with evident hepatic arterial 
branches and portal vein branches. A score of 0 meant interlobular bile ducts were distinguishable in 
all portal tracts in specimens. Score of 1 and 2 meant that bile duct loss was evident in <1/3 and in 
1/3–2/3 of portal tracts, respectively. A score of 3 indicated that bile ducts were absent in >2/3 of 
portal tracts. For Orcein-positive granule deposition, a score of 0 meant no deposition in periportal 
hepatocytes, a score of 1 indicated deposition in some periportal hepatocytes in <1/3 of portal tracts, 
and a score of 3 was given for patients with deposition in many hepatocytes of >2/3 portal tracts or 
fibrous septa. Samples intermediate between 1 and 3 were assigned a score of 2. After each of these 
items was scored, they were summed: a total score of 0 indicated stage 1 (no or minimum 
progression), 1–3, stage 2 (mild progression); 4–6, stage 3 (moderate progression); and 7–9, stage 4 
(advanced progression). 
 
 Statistical analysis: Data were analyzed using Welch’s t-tests, paired t tests, and Spearman rank 




 Serum fractalkine levels and their relationship with serological data: Serum fractalkine 
levels in PBC patients ranged from 0 to 33.2 ng/ml before UDCA treatment, and the mean was 3.2 
ng/ml. However, most values were 0–3.0 ng/ml, and 14 cases showed high levels (>5 ng/ml) (Fig. 1). 
This trend confirmed the findings in our previous report [9], where serum fractalkine levels in all 
controls including healthy controls and patients with extrahepatic biliary obstruction and 
HCV-related chronic hepatitis were <3.0 ng/ml [9]. Next, the correlation between fractalkine levels 
and liver function data (ALT and ALP levels) and IgM levels was examined. The correlation 
Harada  - 7 - 
 
coefficients between fractalkine levels and ALT, ALP, and IgM levels were 0.12, 0.06, and 0.10, 
respectively (Fig. 2A). With regard to autoantibodies, none showed significant positive correlation 
with serum fractalkine levels (Fig. 2B). However, patients with high gp210 titers had low fractalkine 
levels, whereas patients with high serum fractalkine levels had low gp210 titers, except one case in 
which both levels were high (fractalkine, 33.2 ng/ml; gp210, 132.4 times) (Fig. 2B). This patient 
(Fig. 2B, #) was a 35-year-old male positive for both AMA and ANA and had increased IgG and 
IgM levels. His condition rapidly deteriorated despite all treatment and he promptly underwent liver 
transplantation, suggesting the existence of other factors such as autoimmune hepatitis exacerbating 
liver injury. Therefore, we considered this case as an outlier and performed the subsequent statistical 
analysis excluding it. Consequently, the serum fractalkine level of 1.5 ± 0.2 ng/ml (mean ± standard 
error of mean) in patients with high gp210 titers (>5 times) was significantly lower (5.5 ± 1.5 ng/ml) 
than that in patients with low gp210 titers (≤5 times) (Welch’s t-test, p < 0.05). Moreover, gp210 
titers (1.7 ± 0.3 times) in patients with high serum fractalkine levels (>3 ng/ml) were significantly 
lower (35.1 ± 11.1 times) than those in patients with low fractalkine levels (<3 ng/ml) (Welch’s t-test, 
p < 0.05). 
 
 Correlation between serum fractalkine levels and histological activity and staging of 
PBC: Fractalkine levels in PBC patients were analyzed according to the histological activity of 
chronic cholangitis (CA) and hepatitic change (HA). As shown in Fig. 3, fractalkine levels in CA3 
cases were significantly higher than those in cases with other scores (CA0–CA2) and, in contrast, the 
fractalkine levels in HA3 cases were significantly lower than those in cases with other scores 
(HA0–HA2) (Welch’s t-test, p < 0.05) with the exception of one case (Figs. 3A and 3B). As for the 
three histological findings defining histological stage, fibrosis, bile duct loss, and Orcein-positive 
granules, the cases with low scores (0–1) of fibrosis and a score of 0 for Orcein-positive granules 
showed significantly higher fractalkine levels than in cases with a score of 2–3 for fibrosis and 1–3 
for Orcein-positive granules (Figs. 3D and 3F) (Welch’s t-test, p < 0.05). Moreover, the cases with 
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early histological stages (stages 1–2) showed higher fractalkine levels than those with advanced 
stages (stages 3–4) (Fig. 3C). 
 
 Correlation between serum fractalkine levels and UDCA effects: The changes in serum 
fractalkine levels before (before treatment) and 1–2 years after the beginning of UDCA treatment 
(after treatment) are shown in Fig. 4. Most cases with low fractalkine levels (<3.0 ng/ml) before the 
treatment retained low levels. However, 14 cases with high fractalkine levels (>5 ng/ml) showed 
changes over time. Among serum ALP, ALT, and IgM defining the biochemical response to UDCA, 
the patients with >2 items of good response or <1 item of good response were evaluated separately. 
The patients with high fractalkine levels (>5 ng/ml) before treatment showed a decrease after 
treatment in the patients with >2 items of good response, but those with high fractalkine levels 
showed an increase in those with <1 item of good response. Statistical analysis demonstrated that in 
patients with >2 good response items, fractalkine level was significantly decreased after treatment 




 Fractalkine chemoattracts CXCR1-expressing cells in target organs and maintains continuous 
inflammation, ultimately inducing chronic inflammation. We previously reported that damaged bile 
ducts and vessels in PBC express fractalkine and that the induction of fractalkine expression in 
biliary epithelial cells is closely associated with biliary and periductal innate immunity [9,10]. In the 
present study, we measured serum fractalkine levels using different PBC patients’ sera and obtained 
a similar average and distribution. Most cases had levels <3 ng/ml, but 14 patients had high levels 
(>5 ng/ml). These high levels were only observed in PBC patients; levels in the healthy population 
and patients with other liver diseases were <3 ng/ml [9]. Therefore, in PBC patients with high 
fractalkine levels, intrahepatic fractalkine produced by liver constituent cells, including biliary 
epithelial cells, is the likely cause of the increase in serum fractalkine. This indicates that 
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fractalkine-mediated inflammation is associated with chronic cholangitis and portal inflammation. 
 Although a serological hallmark of PBC is the presence of AMA, which is found in >90% of 
patients, ANAs are also detected in PBC patients [13-17]. Anti-gp210 and anti-sp100 antibodies are 
highly specific for PBC and useful for its diagnosis, particularly those who are negative for AMAs 
[13-17]. In addition, although AMAs are not associated with disease progression, ANAs are 
associated with disease severity and are therefore useful as a marker of poor prognosis [15-18]. 
Anti-gp210 antibodies are the strongest predictive factor among ANAs for progression to end-stage 
hepatic failure (i.e., hepatic failure type progression) [15-17]. Moreover, the presence of gp210 
antibodies is a risk factor for more severe interface hepatitis and lobular inflammation defining 
hepatitis activity (HA). The present study revealed that most patients with high gp210 titers had low 
serum fractalkine levels, whereas most patients with high fractalkine levels had low gp210 titers. 
Moreover, the fractalkine levels in the CA3 cases were significantly higher than those with lower 
scores (CA0–CA2). In contrast, fractalkine levels in the HA3 cases were significantly lower than 
those with low scores (HA0-HA2). Therefore, a possible explanation of why high anti-gp210 
antibody and fractalkine levels showed opposite trends with each other except in one unique case 
(Fig. 2B, #) is that the gp210 antibody and fractalkine are associated with marked hepatitic change 
(HA) and chronic cholangitis (CA), respectively, indicating that they may reflect two different 
pathogenetic mechanisms of PBC from the aspects of hepatitis and cholangitis, respectively. The 
unique case showing high gp210 antibody titers and fractalkine levels (Fig. 2B, #) had extensive 
chronic cholangitis (CA2) and hepatitic changes (HA3), as shown in Fig. 3. This PBC case was very 
rare and pathognomonic, and the patient rapidly progressed to Stage 3 liver failure before the 
terminal stage without any improvement achieved with UDCA treatment. This indicates that the case 
was aggressive and had a poor prognosis, suggesting a case of atypical PBC. 
 As discussed above, fractalkine is speculated to be associated with the pathogenesis of chronic 
cholangitis in PBC, which is a characteristic feature of this disease. Moreover, the present study 
revealed that the cases with low fibrosis scores (0–1) and a score of 0 for Orcein-positive granules 
among the three histological findings defining histological stage showed high fractalkine levels, 
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similar to patients in early histological stages (stages 1–2). Therefore, fractalkine plays a role in the 
pathogenesis of chronic cholangitis in PBC, particularly in the early stages, indicating that 
fractalkine is an important factor in initial chronic cholangitis in PBC and also during the transition 
to chronic cholangiopathy in PBC without reference to hepatitic change. However, many PBC 
patients had low serum fractalkine levels, even in the early stages, indicating that the association of 
fractalkine in the pathogenesis of PBC might be varied in each case, and its significance differs 
between early and advanced stages, even in the same patient. 
 The present study demonstrated a correlation between serum fractalkine levels and response to 
UDCA; although patients with low fractalkine levels (<3 ng/ml) before UDCA treatment had low 
levels after treatment irrespective of the effectiveness of UDCA treatment, the cases with high levels 
(>5 ng/ml) showed a decrease or increase after UDCA treatment in good and poor biochemical 
responders, respectively. UDCA is a hydrophilic, nontoxic bile acid that contributes nearly 3% to the 
normal bile acid pool in humans and has cytoprotective, anti-apoptotic, membrane stabilizing, 
antioxidative, and immunomodulatory effects [19]. In our previous study, we demonstrated that 
upregulation of fractalkine expression in biliary epithelial cells is induced by the biliary innate 
immune response [9]. Therefore, it is possible that UDCA directly regulates the production of 
fractalkine in liver constituent cells, including biliary epithelial cells, but further study is needed to 
clarify the direct correlation between the effectiveness of UDCA and serum fractalkine levels. 
 The present study demonstrated that among PBC patients, those with high serum fractalkine 
levels are characterized by low gp210 titers, extensive chronic cholangitis, limited hepatitic change, 
and early-stage PBC. Therefore, fractalkine is speculated to play a role in the initial pathogenesis of 
chronic inflammation in early stage PBC and consequently chronic cholangitis. In addition to PBC, 
fractalkine is associated with chronic inflammation in other diseases, including RA and IBD, and an 
anti-fractalkine monoclonal antibody has been developed as a clinical molecular treatment. 
Collectively, our findings suggest that fractalkine-CX3CR1 signaling might be a useful molecular 
target for the treatment of PBC, particularly in UDCA-ineffective PBC cases with high serum 
fractalkine levels. 
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Fig. 1 Distribution of serum fractalkine levels in PBC patients before UDCA treatment. Levels 
ranged from 0 to 33.2 ng/ml, and the mean was 3.2 ng/ml. Fourteen cases showed high 
fractalkine levels (>5 ng/ml). 
 
Fig. 2A: Correlation between serum fractalkine levels and liver function data (ALT and ALP levels) 
and IgM levels at the time of PBC diagnosis before UDCA treatment. The correlation 
coefficients between fractalkine levels and ALT, ALP, and IgM levels were 0.12, 0.06, and 
0.10, respectively, which were not significant. B: Correlation between serum fractalkine levels 
and autoantibodies at the time of PBC diagnosis before UDCA treatment. The correlation 
coefficients between fractalkine levels and levels of anti-centromere antibody, AMA, and 
gp210 antibody were 0.14, 0.18, and 0.001, respectively, which were not significant. However, 
a clear trend between fractalkine levels and the gp210 antibody titers was found; patients with 
high gp210 titers had low fractalkine levels, and patients with high fractalkine levels had low 
gp210 titers except one case (#). This exceptional case (#) had a high fractalkine level (33.2 
ng/ml) and a high gp210 titer (132.4) and was clinically unique.  
 
Fig. 3 Correlation between serum fractalkine levels and histological activation, stage, and three 
findings defining stage at the time of diagnosis of PBC before UDCA treatment. Serum 
fractalkine was significantly higher in cases with marked chronic cholangitis activity (CA3) 
than those with lower CA scores (CA0–CA2). In contrast, it was lower in cases with marked 
hepatitic activity (HA3) compared with those with lower HA scores (HA0–HA2). Among the 
three histological findings of fibrosis, bile duct loss, and Orcein-positive granules, the cases 
with low scores (0–1) for fibrosis, a score of 0 for Orcein-positive granules, and also early 
stages (stage 1–2) showed significantly higher fractalkine levels than those with a scores of 
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2–3 for fibrosis and 1–3 for Orcein-positive granules, and advanced stages (stage 3–4). The 
statistical analysis was performed without the unique case (#). 
 
Fig. 4 Change in serum fractalkine levels before (before Tx) and 1 or 2 years after the beginning 
UDCA treatment (after Tx). “Total” is the data for all PBC cases. Among the three items 
defining the response to UDCA (serum ALP, ALT, and IgM levels), “good response, >2 items” 
cases with high fractalkine levels (>5 ng/ml) before treatment showed a decrease after 
treatment, whereas “good response, <1 item” cases showed an increase. 






